Reversible cardiogenic shock following 5-Fluorouracil infusion

  • 84 Accesses

  • 1 Citations


5-fluorouracil remains a major component of chemotherapy regimens for various tumors. We report the case of reversible cardiogenic shock following 5-FU administration and discuss the different pitfalls of such toxicity. Oncologist should be aware of that rare but potentially lethal adverse event.

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.


  1. 1.

    Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330–338. doi:10.1038/nrc1074

  2. 2.

    De Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801

  3. 3.

    Meyer CC, Calis KA, Burke LB et al (1997) Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 17:729–736

  4. 4.

    Akhtar SS, Salim KP, Bano ZA (1993) Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: a prospective study. Oncology 50:441–444

  5. 5.

    Grandi AM, Pinotti G, Morandi E, Zanzi P, Bulgheroni P, Guasti L, Bertolini A, Venco A (1997) Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: a one-year follow-up study. Ann Oncol 8(7):705–708. doi:10.1023/A:1008263321681

  6. 6.

    Teixeira L, Barry S, Debourdeau P, Cohen A, Tournigand C (2004) Cardiotoxicity of 5-fluorouracil. Bull Cancer 91(Suppl 3):154–158 Review

  7. 7.

    Freeman NJ, Costanza ME (1988) 5-Fluorouracil-associated cardiotoxicity. Cancer 61(1):36–45. doi:10.1002/1097-0142(19880101)61:1<36::AID-CNCR2820610108>3.0.CO;2-6 Review

  8. 8.

    Mosseri M, Fingert HJ, Varticovski L et al (1993) In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstrication of vascular smooth muscle. Cancer Res 53:3028–3033

  9. 9.

    Südhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W (2004) 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 15(4):661–664. doi:10.1093/annonc/mdh150

  10. 10.

    Mizuno Y, Hokamura Y, Kimura T, Kimura Y, Kaikita K, Yasue H (1995) A case of 5-fluorouracil cardiotoxicity simulating acute myocardial infarction. Jpn Circ J 59:303–307

  11. 11.

    Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME (1994) 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol 10(8):861–864

  12. 12.

    Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M (1996) The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc 10(3):805–818

  13. 13.

    Porta C, Moroni M, Ferrari S, Nastasi G (1998) Endothelin-1 and 5-fluorouracil-induced cardiotoxicity. Neoplasma 45(2):81–82

  14. 14.

    Kuzel T, Esparaz B, Green D, Kies M (1990) Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer 65(4):885–889

  15. 15.

    Barclay BJ, DeHaan CL, Hennig UG, Iavorovska O, von Borstel RW, von Borstel RC (2001) A rapid assay for mitochondrial DNA damage and respiratory chain inhibition in the yeast Saccharomyces cerevisiae. Environ Mol Mutagen 38(2–3):153–158. doi:10.1002/em.1066

  16. 16.

    Peters AK, Steemans M, Hansen E, Mesens N, Verheyen GR, Vanparys P (2008) Evaluation of the embryotoxic potency of compounds in a newly revised high throughput embryonic stem cell test. Toxicol Sci 105(2):342–350. doi:10.1093/toxsci/kfn126

  17. 17.

    Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134(1):75–82. doi:10.1007/s00432-007-0250-9

  18. 18.

    Van Cutsem E, Hoff PM, Blum JL et al (2002) Incidence of cardiotoxicity with oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 13:484–485. doi:10.1093/annonc/mdf108

Download references


The authors thank Lorna Saint Ange for editing.

Author information

Correspondence to Jean-Charles Soria.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Transthoracic echocardiography performed at H18 after 5FU infusion: apical 4 chamber view showing global hypokinesia with a severe LVEF dysfunction measured at 35 %. (MPEG 1204 kb)

Panel 1

Transthoracic echocardiography performed before chemotherapy: apical 4 chamber view showing normal left ventricular ejection fraction (60%). (MPEG 460 kb)

Panel 2

Transthoracic echocardiography performed at H18 after 5FU infusion: apical 4 chamber view showing global hypokinesia with a severe LVEF dysfunction measured at 35 %. (MPEG 1204 kb)

Panel 3

Transthoracic echocardiography performed at Day 7: apical 4 chamber view showing a complete normalization of LVEF (60%). (MPEG 430 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Ferté, C., Gomez Roca, C., Loriot, Y. et al. Reversible cardiogenic shock following 5-Fluorouracil infusion. Invest New Drugs 28, 531–533 (2010) doi:10.1007/s10637-009-9271-3

Download citation


  • 5-Fluorouracil
  • Cardiogenic shock
  • Toxicity